Transitioning to Elecsys automated immunoassay for fresh CSF biomarkers to support the diagnosis of Alzheimer’s disease in Australia

Alzheimer’s disease (AD) biomarker proteins, amyloid β1‐42 (Aβ42) and Tau (Phospho‐tau 181 [pTau] or Total‐tau [tTau]), in the cerebrospinal fluid (CSF) are used to support the clinical diagnosis of AD, and for enrolment of patients into therapeutic trials. Currently Roche Elecsys Generation I (GI) for frozen CSF is used, which will be replaced by Generation II (GII) for routine diagnostics use. This study examined the correlation of the biomarkers obtained from the automated Elecsys GI vs the manual INNOTEST immunoassays and the concordance of diagnostics outcome between the two methods. In addition, we also examined performance of GII on fresh CSF.